Grünenthal agreed to acquire the European rights (excluding Spain and the UK) to AstraZeneca’s Crestor (rosuvastatin) and its associated brands for a total consideration of up to $350 million.
Eisai Inc. announced positive top-line results from the CAMELLIA-TIMI 61 cardiovascular outcome trial.
